#USA #Boston #Clinical Trials #Biotech Showcase #Alzheimer's Drug

CTAD 2026 and ADDF Partnership

The world of Alzheimer's disease research is poised for a significant leap forward with the recent announcement of a partnership between the Clinical Trials on Alzheimer's Disease (CTAD) conference and the Alzheimer's Drug Discovery Foundation (ADDF). Set to take place in Boston from November 16–19, 2026, the CTAD Conference will prominently feature a special Biotech Showcase, focusing on emerging biotechnology companies dedicated to developing innovative treatments and technologies for Alzheimer's and related dementias.

Isobel Coleman, CEO of the ADDF, emphasized the importance of this collaboration, stating that the progress in understanding Alzheimer's disease mechanisms is accelerating and that artificial intelligence is starting to reshape treatment identification and evaluation. This reflects an evolving pipeline of breakthroughs in just five years, with an urgent need for funds and teamwork to bring lab discoveries to patients in need. The Biotech Showcase aims to couple scientific discoveries with the necessary capital and collaboration to translate them effectively into clinical solutions.

As the Alzheimer's drug development landscape becomes increasingly complex with the focus moving towards personalized treatment strategies, the partnership aims to strengthen the clinical development processes. Jacques Touchon, MD, PhD, Co-Founder and Co-Chairman of CTAD, pointed out that rigorous clinical development is more crucial now than ever, and this collaboration strives to forge partnerships and networks that help translate emerging science into real-world progress.

The Biotech Showcase will offer selected biotech firms the platform to present their research and development initiatives to key stakeholders, including industry leaders and investors. These rapid-fire presentations will allow companies to share their scientific findings in three-minute lightning talks, engage with the audience in live Q&A sessions, and receive immediate feedback from prominent Alzheimer's researchers and industry executives. This setup is designed to enhance visibility for these emerging companies while enabling them to form valuable networks that might expedite the clinical development of their promising projects.

The opportunity for further involvement is created as the second cycle for submitting abstracts for the Biotech Showcase opens on September 3, 2026. This will provide more companies the chance to showcase their pioneering research to a wider audience.

The ADDF was founded in 1998 by Leonard A. and Ronald S. Lauder with a mission to expedite the development of drugs intended to prevent, treat, and ultimately cure Alzheimer's disease. As the sole public charity focused exclusively on this aspect, the ADDF employs a venture philanthropy model to support research across academia and the biotech industry. The foundation has played a critical role in advancing significant tools, including the first Alzheimer's PET scan and blood test, along with contributing nearly $400 million to support various Alzheimer's drug development programs internationally.

The CTAD conference, launched back in 2008, has become the foremost global gathering dedicated to clinical investigation of Alzheimer's disease. It draws together a diverse range of professionals including researchers, clinicians, and regulatory experts to facilitate dynamic interdisciplinary discourse. Uniquely, all the sessions at CTAD occur in a single plenary setting, ensuring a uniform experience for all attendees, which is essential when transitioning research outcomes into clinical practice.

This year's CTAD will not only enrich the dialogue about Alzheimer's disease clinical research but also deliberately bridge the gap between scientific advancements and clinical applications. As the conference coincides with the Biotech Showcase, it marks a critical moment in the evolution of Alzheimer's treatments.

By fostering collaborations between biotech innovators and institutional investors, CTAD 2026 and ADDF aim to set a new standard for partnership in the Alzheimer’s research field, ensuring that the latest innovations are translated into actionable therapies for those in need.